Back

Ferric derisomaltose versus usual care in patients with heart failure, reduced ejection fraction, and iron deficiency: a short-term UK cost-utility analysis based on the IRONMAN RCT

1 September 2024 (16:05 - 16:15)
Organised by: Logo
Congress Presentation Part of: Collateral damage in heart failure: comorbidities and their treatment Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Richard Fulton Pollock

Covalence Research Ltd, Harpenden (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Development and validation of a risk prediction model for worsening renal function in patients with incident heart failure
Professor C. Lang (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Prevalent and incident anemia in PARAGON-HF
Doctor H. Lu (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Impact of various iron deficiency definitions on mortality risk in chronic heart failure across the spectrum of left ventricular ejection fraction spectrum.
Doctor A. Mohamed (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Non-linear causal effects of kidney function on the risk of heart failure: a Mendelian randomization study
Doctor J. Liu (Guangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Collateral damage in heart failure: comorbidities and their treatment
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 16:05 CET
You may be interested in
thumbnail
Congress Presentation
Ferric derisomaltose: IRONMAN
thumbnail
Congress Session
Collateral damage in heart failure: comorbidities and their treatment
thumbnail
Congress Presentation
IV iron improves morbidity and (perhaps) mortality

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources